TG Therapeutics | TGTX - Debt


TG Therapeutics reported $253.71M in Debt for its fiscal quarter ending in December of 2025.





Debt Change Date
AbbVie USD 67.5B 67.5B Dec/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Amgen USD 54.6B 17M Dec/2025
Ardelyx USD 207.61M 968K Sep/2025
Arrowhead Research USD 312.77M 53.52M Dec/2025
Bayer EUR 36.45B 2.93B Dec/2025
Biogen USD 6.56B 275.1M Mar/2026
Corcept Therapeutics USD 6.11M 251K Dec/2025
Curis USD 0 0 Jun/2022
Gilead Sciences USD 24.94B 5M Dec/2025
Infinity Pharmaceuticals USD 0 0 Jun/2022
J&J USD 47.93B 2.14B Dec/2025
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Novartis USD 47B 11.62B Mar/2026
Novavax USD 233.31M 4.23M Sep/2024
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 300K Mar/2026
Roche Holding CHF 33.03B 1.41B Jun/2025
TG Therapeutics USD 253.71M 8.37M Dec/2025
Verastem USD 66.79M 26.7M Sep/2024
Vertex Pharmaceuticals USD 1.99B 44M Mar/2026